Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEND-1 in Combination With Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma
CTR20212588Phase 2Completed
- Sponsor
- Cend Therapeutics
- Start
- Oct 2021
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of certepetide in pancreatic adenocarcinoma (PDAC), sponsored by Cend Therapeutics. Started Oct 2021; status: completed.
02
Drugs
certepetide
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20212588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212588.